REMS Program Resources for Clinicians
An expert cardiologist discusses the importance of healthcare provider education and finding resources around the REMS program.
Source: hcplive.com
Jamesl Januzzi News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jamesl Januzzi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jamesl Januzzi Today - Breaking & Trending Today
Role of Mavacamten in Treating oHCM
James L. Januzzi, MD, comments on mavacamten as the first approved cardiac myosin inhibitor for oHCM, balancing the increased risk of heart failure with the medication, and the role of the REMS program.
Source: hcplive.com
Using Cardiac Myosin Inhibitors for the Treatment of oHCM
Dr James L. Januzzi reviews the use of cardiac myosin inhibitors for the management of oHCM.
Source: hcplive.com
Clinical Trial Outcomes for Cardiac Myosin Inhibitors in oHCM Treatment
An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.
Source: hcplive.com
Role of Small-Molecule Myosin Inhibitors in oHCM Treatment
James L. Januzzi, MD, provides insight on the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and comments on small-molecule myosin inhibitors as an emerging therapeutic option.
Source: hcplive.com